엘앤씨바이오

290650KOSDAQ

57.5 / 100

Reference Date: 2026-10-23

Financial Score18.0 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 30.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

L&N Bio is a specialist in regenerative medicine, developing and selling human tissue implants and medical devices, along with cosmetic and pharmaceutical businesses. Its flagship product, Acellular Dermal Matrix (MegaDerm), is used for breast reconstruction after cancer treatment, and the company expands its global market by exporting tissue-based medical devices. It aims to grow into a comprehensive healthcare platform through R&D in regenerative medicine.

Number of Employees

155people

Average Salary

49.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

7.63Industry Average 1.200.0Point

6.4x industry avg (risky)

ROE

-55.32Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.94Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 14.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 59,000Won52-week high 118,30052-week low 45,400

1-month return6.0Point

1m +29.96% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

9 totalPositive 2Neutral 7Negative 0

Neutral증권발행실적보고서2026-10-22
Neutral증권발행결과(자율공시)2026-10-22
Positive유상증자또는주식관련사채등의청약결과(자율공시)2026-10-16
Positive유상증자최종발행가액확정2026-10-12
Neutral[기재정정]주요사항보고서(유무상증자결정)2026-10-12